{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:40:01Z","timestamp":1793893201682,"version":"4.8.0"},"reference-count":164,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>CD24 is a glycosylphosphatidylinositol-anchored surface protein frequently overexpressed in solid tumors and increasingly recognized as an innate immune checkpoint that suppresses macrophage-mediated phagocytosis through engagement of Siglec-10 in humans (Siglec-G in mice). Beyond its associations with tumor aggressiveness and stem-like phenotypes, CD24 functions at a critical interface between tumor-intrinsic plasticity and myeloid-driven immune suppression within the tumor microenvironment (TME). Despite growing therapeutic interest, clinical translation of CD24 targeting has been limited by tumor heterogeneity, redundancy among innate immune checkpoints, safety concerns related to physiological CD24 expression, and the absence of functional biomarker frameworks. In this review, we synthesize recent advances in CD24 biology, biomarker-guided stratification strategies, and emerging CD24-directed therapeutic modalities. We highlight unresolved controversies, define key translational challenges, and propose future directions for integrating CD24 targeting into precision immunotherapy strategies tailored to dominant immune resistance mechanisms in solid tumors.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1798585","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:33:36Z","timestamp":1774506816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["CD24 as an innate immune checkpoint in solid tumors: biology, biomarker stratification, and therapeutic translation"],"prefix":"10.3389","volume":"17","author":[{"given":"Weiwei","family":"Zhou","sequence":"first","affiliation":[{"name":"Henan Provincial People\u2019s Clinical Medical School of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Huang","sequence":"additional","affiliation":[{"name":"Henan Provincial People\u2019s Clinical Medical School of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Henan Provincial People\u2019s Hospital, People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangxin","family":"Lu","sequence":"additional","affiliation":[{"name":"Henan Provincial People\u2019s Clinical Medical School of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxue","family":"Ma","sequence":"additional","affiliation":[{"name":"Sanford Stem Cell Institute, Department of Medicine, Moores Cancer Center, University of California San Diego","place":["La Jolla, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cytogfr.2024.08.006","article-title":"Biomarker discovery in hepatocellular carcinoma (Hcc) for personalized treatment and enhanced prognosis","volume":"79","author":"Yu","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1295684","article-title":"Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs","volume":"14","author":"Shao","year":"2023","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of pd-1\/pd-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41698-025-01152-9","article-title":"Trem2-mediated regulation of myeloid cells in the tumor microenvironment: new insights and therapeutic prospects","volume":"9","author":"Huang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00262-023-03606-0","article-title":"Targeting cd24\/siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1334922","article-title":"Surprising magic of cd24 beyond cancer","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.059327","article-title":"Decoding cd24: roles of chemoradiotherapy resistance and potential as therapeutic targets","volume":"33","author":"Hong","year":"2025","journal-title":"Oncol Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2025.2557281","article-title":"Disrupting siglec-mediated interactions to develop immunotherapies for cancer treatment","volume":"29","author":"Laubli","year":"2025","journal-title":"Expert Opin Ther Targets"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cmet.2022.07.005","article-title":"Cd24-siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder","volume":"34","author":"Wang","year":"2022","journal-title":"Cell Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122662","article-title":"Sonocatalytic oncolysis microbiota curb intrinsic microbiota lactate metabolism and blockade cd24-siglec10 immune escape to revitalize immunological surveillance","volume":"311","author":"Dong","year":"2024","journal-title":"Biomaterials"},{"key":"B11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41388-023-02923-z","article-title":"The hippo-yap signaling pathway drives cd24-mediated immune evasion in esophageal squamous cell carcinoma via macrophage phagocytosis","volume":"43","author":"Zhou","year":"2024","journal-title":"Oncogene"},{"key":"B12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12929-025-01165-3","article-title":"Cd24a knockout results in an enhanced macrophage- and cd8(+) T cell-mediated anti-tumor immune responses in tumor microenvironment in a murine triple-negative breast cancer model","volume":"32","author":"Chan","year":"2025","journal-title":"J BioMed Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1367959","article-title":"Checkpoint cd24 function on tumor and immunotherapy","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-25-0159","article-title":"Targeting myeloid cells for cancer immunotherapy","volume":"13","author":"Blanchard","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.70068","article-title":"Cd24 is a promising immunotherapeutic target for enhancing efficacy of third-generation egfr-tkis on egfr-mutated lung cancer","volume":"45","author":"Liang","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2025-671","article-title":"Abstract 671: development of a diagnostic antibody for cd24 targeted therapy","volume":"85","author":"Chen","year":"2025","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41467-024-44873-4","article-title":"Bispecific bcma\/cd24 car-T cells control multiple myeloma growth","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e011230","DOI":"10.1136\/jitc-2024-011230","article-title":"Targeting mesothelin-cd24 axis repolarizes tumor-associated macrophages to potentiate pd-1 blockade therapy in high-grade serous ovarian cancer","volume":"13","author":"Zhong","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s12672-024-01284-7","article-title":"Cd24 affects the immunosuppressive effect of tumor-infiltrating cells and tumor resistance in a variety of cancers","volume":"15","author":"Zhao","year":"2024","journal-title":"Discov Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e007068","DOI":"10.1136\/jitc-2023-007068","article-title":"Discovery of a novel dual-targeting D-peptide to block cd24\/siglec-10 and pd-1\/pd-L1 interaction and synergize with radiotherapy for cancer immunotherapy","volume":"11","author":"Shen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1401528","article-title":"From mechanism to therapy: the journey of cd24 in cancer","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33249","article-title":"Novel insights into the function of cd24: A driving force in cancer","volume":"148","author":"Altevogt","year":"2021","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216994","article-title":"Cd24 promotes metastasis and chemoresistance by directly targeting arf6-erk pathway in esophageal squamous cell carcinoma","volume":"594","author":"Hong","year":"2024","journal-title":"Cancer Lett"},{"key":"B24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12964-023-01315-w","article-title":"Targeting cd24 as a novel immunotherapy for solid cancers","volume":"21","author":"Yang","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S176654","article-title":"Cd24 expression and stem-associated features define tumor cell heterogeneity and tumorigenic capacities in a model of carcinogenesis","volume":"10","author":"Ortiz-Montero","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e013283","DOI":"10.1136\/jitc-2025-013283","article-title":"Harnessing the innate immune system: A novel bispecific antibody targeting cd47 and cd24 for selective tumor clearance","volume":"13","author":"Nan","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"12245","DOI":"10.1038\/s41598-024-61516-2","article-title":"Epcam-cd24+ Circulating cells associated with poor prognosis in breast cancer patients","volume":"14","author":"Perelmuter","year":"2024","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e2409724122","DOI":"10.1073\/pnas.2409724122","article-title":"Adarp110 promotes hepatocellular carcinoma progression via stabilization of cd24 mrna","volume":"122","author":"Sun","year":"2025","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-17-0367","article-title":"Nuclear cd24 drives tumor growth and is predictive of poor patient prognosis","volume":"77","author":"Duex","year":"2017","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-09-0151","article-title":"Cd24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery","volume":"15","author":"Yang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114041","article-title":"Targeting the gpi transamidase subunit gpaa1 abrogates the cd24 immune checkpoint in ovarian cancer","volume":"43","author":"Mishra","year":"2024","journal-title":"Cell Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1374701","article-title":"Editorial: cd24 in the regulation of cellular development and disease","volume":"15","author":"Christian","year":"2024","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e012391","DOI":"10.1136\/jitc-2025-012391","article-title":"Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy","volume":"13","author":"Pinho","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e70030","DOI":"10.1002\/mog2.70030","article-title":"Targeting immune checkpoints: basic signaling pathways and clinical translation in cancer therapeutics","volume":"4","author":"Sun","year":"2025","journal-title":"MedComm \u2013 Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","article-title":"Emerging phagocytosis checkpoints in cancer immunotherapy","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1228962","article-title":"New hope for tumor immunotherapy: the macrophage-related \u201cDo not eat me\u201d Signaling pathway","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1002\/mco2.349","article-title":"Signaling pathways in macrophages: molecular mechanisms and therapeutic targets","volume":"4","author":"Li","year":"2023","journal-title":"MedComm (2020)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13847","article-title":"Unravelling cd24-siglec-10 pathway: cancer immunotherapy from basic science to clinical studies","volume":"173","author":"Hazra","year":"2024","journal-title":"Immunology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.32604\/or.2023.042383","article-title":"Opportunities and challenges of cd47-targeted therapy in cancer immunotherapy","volume":"32","author":"Chen","year":"2023","journal-title":"Oncol Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jare.2024.12.043","article-title":"Targeting macrophages in cancer immunotherapy: frontiers and challenges","volume":"76","author":"Liu","year":"2025","journal-title":"J Adv Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1186\/s12964-025-02486-4","article-title":"Genetically platform presenting cd24 scfv enhance antitumor immunity by restoring macrophage phagocytosis and modulating the immune environment","volume":"23","author":"Zhou","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.34133\/bmr.0294","article-title":"Targeting microbe-mediated macrophage education: A novel paradigm in cancer immunotherapy","volume":"29","author":"Xu","year":"2025","journal-title":"Biomater Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1176370","article-title":"Cd24-fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1456-0","article-title":"Cd24 signalling through macrophage siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41523-026-00895-3","article-title":"CD52 signaling via macrophage siglec-G represents a therapeutic target for cancer immunotherapy","volume":"12","author":"Qin","year":"2026","journal-title":"NPJ Breast Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"15072","DOI":"10.3390\/ijms242015072","article-title":"Emerging immune checkpoint molecules on cancer cells: CD24 and CD200","volume":"24","author":"Moon","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2023.10.009","article-title":"Deciphering the role of cd47 in cancer immunotherapy","volume":"63","author":"Liu","year":"2024","journal-title":"J Adv Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027222","article-title":"Targeting cd47: many misses; hopeful for a hit","volume":"145","author":"Wilde","year":"2025","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.102496","article-title":"Cd24-targeted cystine and glucose oxidase cascade catalytic nanosystem triggers disulfidptosis in neuroblastoma","volume":"35","author":"Mi","year":"2025","journal-title":"Mater Today Bio"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.071708","article-title":"Cd47-targeted therapy in cancer immunotherapy: at a crossroads of promise and challenge","volume":"33","author":"Guo","year":"2025","journal-title":"Oncol Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1686180","article-title":"A cd47 antibody with minimized erythrocyte and thrombocyte toxicities","volume":"15","author":"Pei","year":"2025","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02715-6","article-title":"Clinical landscape of macrophage-reprogramming cancer immunotherapies","volume":"131","author":"Rannikko","year":"2024","journal-title":"Br J Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1676338","article-title":"Advances in tumor-associated macrophage-mediated chemotherapeutic resistance in glioma","volume":"13","author":"Liu","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1679271","article-title":"Emerging macrophage-based therapies for cancer: A review of preclinical and clinical advances","volume":"16","author":"Brancewicz","year":"2025","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1174789","article-title":"Cd24-siglec interactions in inflammatory diseases","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"qiaf141","DOI":"10.1093\/jleuko\/qiaf141","article-title":"Human CD24+CD38+ regulatory B cells promote pro-resolving macrophage function through the synergistic effect of il-10 and pd-L1","volume":"117","author":"Abdolahinia","year":"2025","journal-title":"J Leukoc Biol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1038\/s41467-024-49825-6","article-title":"An in-situ peptide-antibody self-assembly to block cd47 and cd24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"B59","article-title":"Clinical relevance of stem cell surface markers cd133, cd24, and cd44 in colorectal cancer","volume":"11","author":"Huang","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.4c08947","article-title":"Mir-210 mediated hypoxic responses in pancreatic ductal adenocarcinoma","volume":"9","author":"Mortoglou","year":"2024","journal-title":"ACS Omega"},{"key":"B61","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3892\/ol.2021.12817","article-title":"Integrin alpha5 promotes migration and invasion through the fak\/stat3\/akt signaling pathway in icotinib-resistant non-small cell lung cancer cells","volume":"22","author":"Yang","year":"2021","journal-title":"Oncol Lett"},{"key":"B62","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41420-024-01858-y","article-title":"Cd24 induced cellular quiescence-like state and chemoresistance in ovarian cancer cells via mir-130a\/301a-dependent cdk19 downregulation","volume":"10","author":"Jang","year":"2024","journal-title":"Cell Death Discov"},{"key":"B63","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","article-title":"Cancer stem cells: landscape, challenges and emerging therapeutic innovations","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e2502758","DOI":"10.1002\/adma.202502758","article-title":"Signal transducer nanoparticles enable siglec-10\/G blockade immunotherapy for breast cancer treatment","volume":"37","author":"Meng","year":"2025","journal-title":"Adv Mater"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e010767","DOI":"10.1136\/jitc-2024-010767","article-title":"Targeted release of a bispecific fusion protein sirpalpha\/siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors","volume":"13","author":"Zhang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.3390\/biomedicines11123159","article-title":"Targeting cd24 in cancer immunotherapy","volume":"11","author":"Chen","year":"2023","journal-title":"Biomedicines"},{"key":"B67","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s43066-024-00343-6","article-title":"Plasma cd24 level as a promising prognostic biomarker of hepatocellular carcinoma","volume":"14","author":"Rasmy","year":"2024","journal-title":"Egyptian Liver J"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1986_23","article-title":"Cd24 and tumor budding as a prognostic variable in carcinoma gall bladder: A pilot study","volume":"21","author":"Dubey","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/omi.2020.0185","article-title":"Cancer stem cell markers in relation to patient survival outcomes: lessons for integrative diagnostics and next-generation anticancer drug development","volume":"25","author":"Dzobo","year":"2021","journal-title":"OMICS"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6074.Tumimm24-a055","article-title":"Abstract A055: cd47 predominates over cd24 as a macrophage immune checkpoint in cancer","volume":"12","author":"Meglan","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08257-4","article-title":"Cancer cells impair monocyte-mediated T cell stimulation to evade immunity","volume":"637","author":"Elewaut","year":"2025","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","first-page":"8219","DOI":"10.3390\/ijms26178219","article-title":"Profiling of breast cancer stem cell types\/states shows the role of cd44(Hi)\/cd24(Lo)-aldh1(Hi) as an independent prognostic factor after neoadjuvant chemotherapy","volume":"26","author":"Ghebeh","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-007-0091-5","article-title":"Cd24 expression is an independent prognostic marker in cholangiocarcinoma","volume":"11","author":"Agrawal","year":"2007","journal-title":"J Gastrointest Surg"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e44298","DOI":"10.1097\/MD.0000000000044298","article-title":"Cd24 expression for better outcome prediction in newly diagnosed multiple myeloma patients","volume":"104","author":"Wang","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0619","article-title":"Cd24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis","volume":"65","author":"Baumann","year":"2005","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1186\/s12967-025-07370-w","article-title":"Recent progress in immune evasion mechanisms of triple-negative breast cancer","volume":"23","author":"Yang","year":"2025","journal-title":"J Transl Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S409054","article-title":"Cd24 may serve as an immunotherapy target in triple-negative breast cancer by regulating the expression of pd-L1","volume":"15","author":"Zhu","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1183285","article-title":"The biological roles of cd24 in ovarian cancer: old story, but new tales","volume":"14","author":"Gu","year":"2023","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0607","article-title":"Cd24+ Ovarian cancer cells are enriched for cancer-initiating cells and dependent on jak2 signaling for growth and metastasis","volume":"14","author":"Burgos-Ojeda","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02448-x","article-title":"The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma","volume":"41","author":"Evan","year":"2022","journal-title":"Oncogene"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573522","article-title":"Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma","volume":"16","author":"Ramesh","year":"2025","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167117","article-title":"Unraveling the role of cd24 in hepatocellular carcinoma: involvement of inactivated hippo signaling and sox4-mediated regulation","volume":"1870","author":"He","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B83","doi-asserted-by":"publisher","first-page":"497","DOI":"10.7754\/Clin.Lab.2017.171012","article-title":"Cd24 overexpression related to lymph node invasion and poor prognosis of colorectal cancer","volume":"64","author":"Wang","year":"2018","journal-title":"Clin Lab"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02351-7","article-title":"Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer","volume":"57","author":"Aung","year":"2025","journal-title":"Nat Genet"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.01.061","article-title":"Expression of cd24 in clear cell renal cell carcinoma and its prognostic significance","volume":"72","author":"Lee","year":"2008","journal-title":"Urology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11264","article-title":"Up-regulation of cytoplasmic cd24 expression is associated with Malignant transformation but favorable prognosis of colorectal adenocarcinoma","volume":"36","author":"Yeo","year":"2016","journal-title":"Anticancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218015","article-title":"Cancer stem cell mechanisms and targeted therapeutic strategies in head and neck squamous cell carcinoma","volume":"634","author":"Maharajan","year":"2025","journal-title":"Cancer Lett"},{"key":"B88","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1038\/s41467-023-40271-4","article-title":"Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response","volume":"14","author":"Arora","year":"2023","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1186\/s40001-025-03003-6","article-title":"Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives","volume":"30","author":"Zafar","year":"2025","journal-title":"Eur J Med Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/cells14100741","article-title":"Tumor-associated macrophages: polarization, immunoregulation, and immunotherapy","volume":"14","author":"Saeed","year":"2025","journal-title":"Cells"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218391","article-title":"Unraveling pancreatic ductal adenocarcinoma at single-cell resolution with spatial insights: from mechanisms to clinical translation","volume":"645","author":"Qi","year":"2026","journal-title":"Cancer Lett"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1600261","article-title":"Immunotherapy biomarkers in brain metastases: insights into tumor microenvironment dynamics","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e70256","DOI":"10.1002\/mco2.70256","article-title":"Macrophage signaling pathways in health and disease: from bench to bedside applications","volume":"6","author":"Chi","year":"2025","journal-title":"MedComm (2020)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113740","article-title":"Ppab001, a novel bispecific antibody against cd47 and cd24, enhances anti-pd-L1 efficacy in triple-negative breast cancer via reprogramming tumor-associated macrophages towards M1 phenotype","volume":"144","author":"Yang","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e71443","DOI":"10.1002\/cam4.71443","article-title":"Overexpressed cd24 and cd47 indicate a worse prognosis in cervical cancer","volume":"14","author":"Yu","year":"2025","journal-title":"Cancer Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"31530","DOI":"10.1038\/s41598-024-83145-5","article-title":"Expression and relationship of pd-L1, cd24, and cd47 in hepatitis B virus associated hepatocellular carcinoma","volume":"14","author":"Lin","year":"2024","journal-title":"Sci Rep"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.ccell.2024.11.002","article-title":"Myeloid effector cells in cancer","volume":"42","author":"Schol","year":"2024","journal-title":"Cancer Cell"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1038\/s41598-022-25072-x","article-title":"Cd24-associated cerna network reveals prognostic biomarkers in breast carcinoma","volume":"13","author":"Yu","year":"2023","journal-title":"Sci Rep"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1612623","article-title":"Integrated multi-omics analysis of single-cell and spatial transcriptomics reveals distinct hpv-associated immune microenvironment features and prognostic signatures in cervical cancer","volume":"16","author":"Su","year":"2025","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3390\/cancers16061213","article-title":"Advancements in circulating tumor cell research: bridging biology and clinical applications","volume":"16","author":"Salu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B102","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B103","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/cells12060869","article-title":"Evaluation and application of drug resistance by biomarkers in the clinical treatment of liver cancer","volume":"12","author":"Huang","year":"2023","journal-title":"Cells"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e192883","DOI":"10.1172\/JCI192883","article-title":"RCC2 and CD24 cooperate to modulate prostate cancer progression through vimentin ubiquitination and beta-catenin activation","volume":"135","author":"Cui","year":"2025","journal-title":"J Clin Invest"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13714","article-title":"Prospects of antibodies targeting cd47 or cd24 in the treatment of glioblastoma","volume":"27","author":"Wu","year":"2021","journal-title":"CNS Neurosci Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.100747","article-title":"Dual blockade of cd47 and cd24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy","volume":"31","author":"Yang","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"B107","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"B108","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40291-024-00734-w","article-title":"Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors","volume":"28","author":"Gu","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.08.009","article-title":"Glycan targeting nanoparticle for photodynamic immunotherapy of melanoma","volume":"13","author":"Choi","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B110","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/pharmaceutics17070888","article-title":"Nanotechnology approaches for mitigating biologic immunogenicity: A literature review","volume":"17","author":"Alanazi","year":"2025","journal-title":"Pharmaceutics"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01668-1","article-title":"Multifunctional nanoparticle-mediated combining therapy for human diseases","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.09.029","article-title":"Trained immunity modulators: A new frontier in immunoregulation and disease intervention","author":"Chen","year":"2025","journal-title":"J Adv Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152975","article-title":"Silent cd24-engineered oncolytic virus vaccine enhances antitumor immunity","volume":"792","author":"Xu","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"B115","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.3390\/ijms26146900","article-title":"Systemic delivery strategies for oncolytic viruses: advancing targeted and efficient tumor therapy","volume":"26","author":"Xia","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.31083\/FBL41097","article-title":"Innate priming and tumor-associated macrophage reprogramming: A commentary on emerging immunotherapeutic strategies","volume":"30","author":"Balkhi","year":"2025","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.3390\/ijms25063414","article-title":"New strategies for macrophage re-education in cancer: an update","volume":"25","author":"Lampiasi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2025.2504376","article-title":"Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers","volume":"30","author":"Li","year":"2025","journal-title":"Expert Opin Emerg Drugs"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101933","article-title":"Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatment","volume":"32","author":"Lin","year":"2025","journal-title":"Mater Today Bio"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-0597","article-title":"Cd24-targeted car-T cells mediated long-term antitumor efficacy through activation of endogenous tumor immune responses","volume":"24","author":"Huang","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00557","article-title":"Gata3 encapsulated by tumor-associated macrophage-derived extracellular vesicles promotes immune escape and chemotherapy resistance of ovarian cancer cells by upregulating the cd24\/siglec-10 axis","volume":"20","author":"Chen","year":"2023","journal-title":"Mol Pharm"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03491-7","article-title":"Cd24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer","volume":"72","author":"Yang","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.3390\/cancers17172898","article-title":"Advancing car T-cell therapy in solid tumors: current landscape and future directions","volume":"17","author":"Rafii","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B124","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.3390\/ijms26199587","article-title":"Special issue \u201cthe promising future of car-based therapies: A matter of molecular details","volume":"26","author":"Nicolini","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B125","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"Car-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B126","doi-asserted-by":"publisher","first-page":"58 p","DOI":"10.3390\/ijms27010058","article-title":"The myeloid biomarker ms4a6a drives an immunosuppressive microenvironment in glioblastoma via activation of the pge2 signaling axis","volume":"27","author":"Chen","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B127","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12943-025-02481-w","article-title":"Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy","volume":"24","author":"Coelho","year":"2025","journal-title":"Mol Cancer"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3390\/antiox14121474","article-title":"The redox-adhesion-exosome (Rax) hub in cancer: lipid peroxidation-driven emt plasticity and ferroptosis defense with hne\/mda signaling and lipidomic perspectives","volume":"14","author":"Park","year":"2025","journal-title":"Antioxidants (Basel)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546172","article-title":"Tandem car-T cell therapy: recent advances and current challenges","volume":"16","author":"Gomez-Melero","year":"2025","journal-title":"Front Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.270167","article-title":"Cd24 as a novel radiopharmaceutical target for hepatocellular carcinoma","volume":"66","author":"Makala","year":"2025","journal-title":"J Nucl Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-026-04046-y","article-title":"Silencing cd24 inhibits proliferation, migration, and chemoresistance in triple-negative breast cancer cells","author":"Liu","year":"2026","journal-title":"Pharm Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1038\/s41598-026-37588-7","article-title":"Mitoxantrone alters cd24\/siglec-10 expression in Malignant brain tumor models","volume":"16","author":"Kopecky","year":"2026","journal-title":"Sci Rep"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v32.i3.113187","article-title":"Stemness cd24 activation promotes hepatocellular carcinoma progression via an immune escape mechanism","volume":"32","author":"Cai","year":"2026","journal-title":"World J Gastroenterol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2026.150649","article-title":"Cd24 overexpression confers resistance to pyrotinib through inhibiting autophagy in patients with her2-positive breast cancer","volume":"346","author":"Gao","year":"2026","journal-title":"Int J Biol Macromol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1186\/s12951-024-03051-w","article-title":"Ultrasound nanodroplets loaded with siglec-G sirna and fe(3)O(4) activate macrophages and enhance phagocytosis for immunotherapy of triple-negative breast cancer","volume":"22","author":"Yin","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101827","article-title":"Enzyme-instructed self-assembled supramolecular bi-antibodies for inhibition and imaging of atherosclerosis progression","volume":"32","author":"Bian","year":"2025","journal-title":"Mater Today Bio"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c16991","article-title":"Optimizing exosome lipid hybrid nanoparticles for enhanced sirna delivery and improved therapeutic anticancer efficacy in vivo","volume":"19","author":"Abdel-Bar","year":"2025","journal-title":"ACS Nano"},{"key":"B138","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bioactmat.2025.03.016","article-title":"Nanotherapeutic strategies exploiting biological traits of cancer stem cells","volume":"50","author":"Wang","year":"2025","journal-title":"Bioact Mater"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"B140","doi-asserted-by":"publisher","first-page":"e70346","DOI":"10.1002\/mco2.70346","article-title":"Cancer immunotherapy in combination with radiotherapy and\/or chemotherapy: mechanisms and clinical therapy","volume":"6","author":"Wang","year":"2025","journal-title":"MedComm (2020)"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.08.017","article-title":"Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer","volume":"77","author":"Le Saux","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-025-02411-w","article-title":"Advances and obstacles of T cell-based immunotherapy in gynecological Malignancies","volume":"24","author":"Zhao","year":"2025","journal-title":"Mol Cancer"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1111\/odi.14367","article-title":"Cd24 blockade promotes anti-tumor immunity in oral squamous cell carcinoma","volume":"30","author":"Zou","year":"2024","journal-title":"Oral Dis"},{"key":"B144","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/cancers13040806","article-title":"Tumor heterogeneity: A great barrier in the age of cancer immunotherapy","volume":"13","author":"El-Sayes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s12672-025-03322-4","article-title":"Role of intratumoral heterogeneity in metastatic progression and drug resistance","volume":"16","author":"Sinai Borker","year":"2025","journal-title":"Discov Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1695689","article-title":"Multi-scale data reveal a cd24(+) mucl1(+) tumor subgroup associated with unfavorable prognosis in er+ Breast cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116463","article-title":"Metabolic regulation of immunity in the tumor microenvironment","volume":"44","author":"Li","year":"2025","journal-title":"Cell Rep"},{"key":"B148","doi-asserted-by":"publisher","first-page":"eadt5708","DOI":"10.1126\/sciadv.adt5708","article-title":"Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning","volume":"11","author":"Mehari","year":"2025","journal-title":"Sci Adv"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2024.101887","article-title":"Siglecs as modulators of macrophage phenotype and function","volume":"73","author":"Kukan","year":"2024","journal-title":"Semin Immunol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"37816","DOI":"10.1038\/s41598-025-21775-z","article-title":"Circulating cd24\/siglec-10 biomarkers predict post-resuscitation outcomes in a cardiac arrest cohort","volume":"15","author":"Liu","year":"2025","journal-title":"Sci Rep"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3390\/pharmaceutics15061600","article-title":"Emerging preclinical applications of humanized mouse models in the discovery and validation of novel immunotherapeutics and their mechanisms of action for improved cancer treatment","volume":"15","author":"Karnik","year":"2023","journal-title":"Pharmaceutics"},{"key":"B152","doi-asserted-by":"publisher","first-page":"e011279","DOI":"10.1136\/jitc-2024-011279","article-title":"Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic","volume":"13","author":"Eguren-Santamaria","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B153","doi-asserted-by":"publisher","first-page":"e10293","DOI":"10.1002\/adma.202510293","article-title":"Nanomedicine reimagined: translational strategies for precision tumor theranostics","volume":"38","author":"Wu","year":"2025","journal-title":"Adv Mater"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S554821","article-title":"Bridging the gap: the role of advanced formulation strategies in the clinical translation of nanoparticle-based drug delivery systems","volume":"20","author":"Herdiana","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-0943","article-title":"Integration of clinical trial spatial multiomics analysis and virtual clinical trials enables immunotherapy response prediction and biomarker discovery","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1664443","article-title":"Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies","volume":"16","author":"Catani","year":"2025","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","article-title":"New clinical trial design in precision medicine: discovery, development and direction","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B158","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3390\/biology13050307","article-title":"Current landscape of cancer immunotherapy: harnessing the immune arsenal to overcome immune evasion","volume":"13","author":"Mitra","year":"2024","journal-title":"Biol (Basel)"},{"key":"B159","doi-asserted-by":"publisher","first-page":"e70553","DOI":"10.1002\/mco2.70553","article-title":"Single-cell and spatial multiomics: applications for diseases","volume":"6","author":"Li","year":"2025","journal-title":"MedComm (2020)"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1383932","article-title":"Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging","volume":"15","author":"Scheuermann","year":"2024","journal-title":"Front Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/cimb47090753","article-title":"Interpretable transfer learning for cancer drug resistance: candidate target identification","volume":"47","author":"Zhang","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"e012118","DOI":"10.1136\/jitc-2025-012118","article-title":"CD24 recruits tumor-associated neutrophils to promote the progression of hepatocellular carcinoma","volume":"13","author":"Wang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B163","doi-asserted-by":"publisher","first-page":"e70275","DOI":"10.1002\/sim.70275","article-title":"Adaptive biomarker-based design for early phase clinical trials","volume":"44","author":"Serra","year":"2025","journal-title":"Stat Med"},{"key":"B164","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.3390\/jcm14186680","article-title":"Immune checkpoint inhibitors beyond progression in various solid tumors: A systematic review and pooled analysis","volume":"14","author":"Petrelli","year":"2025","journal-title":"J Clin Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1798585\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:33:38Z","timestamp":1774506818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1798585\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":164,"alternative-id":["10.3389\/fimmu.2026.1798585"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1798585","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"article-number":"1798585"}}